News - ALK mutation - LARVOL VERI

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy (clinicaltrials.gov)

P2, N=13, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027

2 days ago

Trial completion date • Trial primary completion date

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)

EGFR mutation • ALK mutation

Imfinzi (durvalumab)

A Single-Arm, Open-Label, Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors (clinicaltrials.gov)

P2, N=56, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

2 days ago

New P2 trial

EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • RET fusion • ALK fusion • ALK mutation • RET mutation • ROS1 fusion • EGFR positive • NTRK fusion

Avastin (bevacizumab) • etoposide IV • utidelone IV (UTD1)

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative (clinicaltrials.gov)

P2/3, N=427, Suspended, National Cancer Institute (NCI) | Trial completion date: Dec 2027 --> Dec 2030 | Trial primary completion date: Dec 2027 --> Dec 2030

3 days ago

Trial completion date • Trial primary completion date

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

PD-L1 expression • ALK mutation

Opdivo (nivolumab) • Yervoy (ipilimumab) • paclitaxel • ABP 206 (nivolumab biosimilar)

Ribosomal profiling of the geniculate ganglion identifies the receptor ALK as critical for the development and maintenance of oral sensory neurons. (PubMed, J Neurosci)

Treatment of cancer patients with selective ALK inhibitors, such as Ceritinib, causes dysgeusia. Mice receiving Ceritinib had a dramatic reduction in taste bud volume and innervation, and a significant portion of PHOX2B+ neurons died, demonstrating that ALK is critical for development and maintenance of oral sensory neurons.

4 days ago

Journal

ALK (Anaplastic lymphoma kinase) • PHOX2B (Paired Like Homeobox 2B)

ALK mutation

Zykadia (ceritinib)

Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS -mutant neuroblastoma. (PubMed, bioRxiv)

As such, the BCL-2 inhibitor venetoclax further enhanced RMC-6236-mediated killing by disrupting RMC-6236 enhanced BIM:BCL-2 complexes. RMC-6236 is a clinically relevant drug that can successfully target the MAPK pathway in these cancers. This study supports expanded clinical testing of this novel therapy to this important subset of neuroblastoma.

8 days ago

Journal • IO biomarker

KRAS (KRAS proto-oncogene GTPase) • NF1 (Neurofibromin 1) • BCL2L11 (BCL2 Like 11)

RAS mutation • ALK mutation

Venclexta (venetoclax) • daraxonrasib (RMC-6236)

The relationship between genetic mutations and organ metastasis in non-small cell lung cancer. (PubMed, Ther Adv Med Oncol)

This review summarizes the associations between genetic mutations and metastatic sites, explores underlying molecular mechanisms, and discusses mutation-based risk prediction and personalized therapeutic strategies. With multi-omics integration and further clinical research, genetic profiling may become a key tool for guiding metastasis prevention, early intervention, and treatment optimization in NSCLC.

9 days ago

Review • Journal

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)

TP53 mutation • KRAS mutation • EGFR mutation • STK11 mutation • ALK mutation • KEAP1 mutation

FMT-LUNG: Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC (clinicaltrials.gov)

P2, N=15, Not yet recruiting, Se-Hoon Lee

9 days ago

New P2 trial • Checkpoint inhibition

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)

EGFR mutation • ALK mutation

Tevimbra (tislelizumab-jsgr)

11d

Coexistence of a primary ALK-positive and MET14 exon skipping mutation double-fusion in one patient with NSCLC and response to crizotinib: A case report and literature review. (PubMed, Medicine (Baltimore))

This report supports crizotinib can provide potential benefit for anaplastic lymphoma kinase/MET14 co-mutated lung adenocarcinoma patients, but sufficient cases and further research are needed to confirm and explore the possible mechanisms involved.

11 days ago

Review • Journal

ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • EML4 (EMAP Like 4)

ALK positive • MET exon 14 mutation • ALK mutation

Xalkori (crizotinib)

11d

LIVIGNO-4: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)

P2/3, N=840, Recruiting, AbbVie | Active, not recruiting --> Recruiting | N=167 --> 840

11 days ago

Enrollment open • Enrollment change • Adverse events

ALK (Anaplastic lymphoma kinase)

ALK mutation

Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)

12d

Sustained Complete Response to Brigatinib in a Young Patient With ALK-Positive NSCLC Harboring I1171N Mutation Post-Alectinib Resistance. (PubMed, Case Rep Oncol Med)

Brigatinib was initiated, and a complete radiologic response was documented within 3 months and has been sustained for over 12 months, including durable intracranial disease control. Sustained CR in I1171N-mediated alectinib resistance is rare and highlights the critical role of repeat molecular testing to guide ALK TKI sequencing.

12 days ago

Journal

ALK (Anaplastic lymphoma kinase)

ALK positive • ALK rearrangement • ALK mutation

Alecensa (alectinib) • Alunbrig (brigatinib)

15d

Pan-cancer analysis of ALK mutation and its association with tumor immunogenicity and the efficacy of immune checkpoint blockade. (PubMed, Genes Dis)

In conclusion, ALK mutation is associated with promoted cancer immunity and can be treated as a biomarker for favorable outcomes in pan-cancer immune checkpoint blockade. These results have implications for treatment decision-making and developing immunotherapy for personalized care.

15 days ago

Journal • Checkpoint inhibition • IO biomarker • Pan tumor

ALK (Anaplastic lymphoma kinase)

ALK mutation

20d

The Bone Microenvironment and Therapeutic Resistance in Spinal Metastases: Mechanisms and Clinical Implications. (PubMed, J Clin Neurosci)

The vertebral niche constitutes a treatment-resistant microenvironment where dormant tumor cells persist, immune surveillance is impaired, and resistant clones evolve. Integrating bone-microenvironment biology with molecular profiling, liquid biopsy, and advanced imaging is essential for refining prognostic models, guiding intervention timing, and designing spine-specific clinical trials. By reframing spinal metastases as a biologically and therapeutically distinct disease entity, this review establishes a framework for developing bone-directed treatment strategies and advancing precision oncology in metastatic spine care.

20 days ago

Review • Journal • BRCA Biomarker

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • BRCA (Breast cancer early onset)

EGFR mutation • EGFR T790M • ALK mutation • BRCA mutation